Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × Temozolomide × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 23 Glioma 12 Sarcoma, Ewing 7 Gliosarcoma 7 Brain Neoplasms 7 Astrocytoma 6 Sarcoma 4 Rhabdomyosarcoma 4 Neuroblastoma 4 Recurrence 3 Osteosarcoma 3 Neoplasm Metastasis 3 Medulloblastoma 3 Ependymoma 3 Diffuse Intrinsic Pontine Glioma 3 Small Cell Lung Carcinoma 2 Lymphoma, Follicular 2 Lymphoma 2 Desmoplastic Small Round Cell Tumor 2 Colorectal Neoplasms 2 Wilms Tumor 1 Somatostatinoma 1 Rhabdoid Tumor 1 Prostatic Neoplasms 1 Pheochromocytoma 1 Paraganglioma 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Oligodendroglioma 1 Neuroectodermal Tumors, Primitive, Peripheral 1

Interventions

pembrolizumab 22 Cyclophosphamide 15 Carboplatin 10 Bevacizumab 9 Paclitaxel 8 Doxorubicin 8 Pemetrexed 7 Nivolumab 7 fludarabine 6 durvalumab 6 atezolizumab 6 Rituximab 6 Fulvestrant 6 Dexamethasone 6 Trastuzumab 5 Standard of Care 5 Prednisone 5 Interviews as Topic 5 Focus Groups 5 Fluorouracil 5 Cisplatin 5 Cetuximab 5 Blood Specimen Collection 5 pertuzumab 4 olaparib 4 Radiotherapy 4 Leucovorin 4 Lenalidomide 4 Gemcitabine 4 Biopsy 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07195591 2026-03-04

BRIDGES

GT Medical Technologies, Inc.

Phase 3 Recruiting

Glioblastoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡